Evidence Review
Depression: Head-to-Head Trials Against Pharmaceuticals
The most striking feature of the saffron research literature is that multiple independent RCTs have pitted it directly against standard antidepressants — not just placebo — and found equivalent efficacy.
Akhondzadeh et al. 2004 (PMID 15341662) ran a 6-week double-blind RCT in 30 adults with mild to moderate depression (DSM-IV criteria), comparing saffron petal extract 30 mg/day to imipramine 100 mg/day. The Hamilton Depression Rating Scale (HDRS) improved in both groups, with no statistically significant difference between treatments at week 6 (p > 0.05). Notably, imipramine produced significantly more anticholinergic side effects (dry mouth, sedation, constipation), while saffron was well-tolerated throughout.
Noorbala et al. 2005 (PMID 15707766) enrolled 40 outpatients with major depressive disorder in a 6-week double-blind trial comparing saffron stigma extract 30 mg/day to fluoxetine 20 mg/day. Both groups showed significant improvement in HDRS scores from baseline, with no significant difference between groups at endpoint (p = 0.71). The saffron group showed a mean HDRS reduction from 22.0 to 10.6; the fluoxetine group from 22.3 to 10.5 — essentially identical. Sample size was small (n = 40), which limits conclusions but is consistent with a genuine equivalence finding.
Ghajar et al. 2017 (PMID 27701683) scaled up to 66 patients with major depressive disorder with anxious distress, comparing saffron 30 mg/day to citalopram 40 mg/day for 6 weeks. Primary outcomes were HDRS and HAM-A (anxiety). No significant difference was found for either outcome between groups (HDRS p = 0.984; HAM-A p = 0.879). This is the largest of the saffron-vs.-SSRI trials and covers both depression and anxiety dimensions simultaneously. The trial was designed with equivalence in mind and was adequately powered for its primary endpoints.
The systematic review by Lopresti and Drummond 2014 (PMID 25384672) synthesized 6 RCTs and concluded that saffron and its constituents demonstrate antidepressant properties comparable to imipramine and fluoxetine, with a consistent mechanism hypothesis involving serotonin, dopamine, and norepinephrine reuptake inhibition alongside anti-inflammatory and antioxidant activity. The authors note methodological limitations common to the field (small sample sizes, primarily Iranian research groups) but judged the overall body of evidence to be meaningful.
Anxiety: Randomized Trial in Adolescents
Lopresti et al. 2018 (PMID 29510352) is particularly notable because it tested a standardized saffron extract (affron, 14 mg twice daily) in 80 adolescents aged 12–16 — a population where psychiatric medication use raises particular concerns. The 8-week double-blind, placebo-controlled RCT found significantly greater improvements in the affron group for separation anxiety (p = 0.003), social phobia (p = 0.023), and depressive symptoms (p = 0.016). The affron group showed approximately 33% improvement in anxiety scores versus 17% in the placebo group. No serious adverse events were reported. This is one of the stronger placebo-controlled designs in the saffron literature and its population (adolescents) is clinically underserved by safe, evidence-based options.
Eye Health: AMD and Retinal Function
Falsini et al. 2010 (PMID 20688744) conducted a crossover RCT in 25 patients with early AMD, randomizing participants to saffron 20 mg/day or placebo for 90 days before crossing over. Outcome measures used focal electroretinogram (ERG) — an objective electrophysiological measure of retinal photoreceptor function. Saffron supplementation significantly increased focal ERG amplitude (p < 0.01) and improved detection thresholds compared to placebo. Critically, the improvements were reversible: retinal function declined again during the placebo phase of the crossover. This reversibility actually strengthens the causal interpretation — a spontaneous recovery or placebo effect would not be expected to reverse predictably in this way. The mechanism is thought to involve crocin/crocetin's protection of photoreceptor cell membrane fatty acids from oxidative degradation, and modulation of the mammalian target of rapamycin (mTOR) pathway which regulates photoreceptor survival.
Mechanisms: Bioactive Compounds
Cerdá-Bernad et al. 2022 (PMID 33356506) provides a comprehensive mechanistic review of all three major saffron bioactives:
- Crocin/crocetin: Water- and fat-soluble forms of the same carotenoid backbone; potent antioxidants that reduce malondialdehyde and nitric oxide (markers of oxidative stress) and upregulate endogenous antioxidant enzymes (glutathione, superoxide dismutase, catalase). Anti-inflammatory via NF-κB inhibition. Cross both the blood-brain barrier and blood-retinal barrier.
- Safranal: The volatile aldehyde responsible for saffron's aroma; primary contributor to serotonin reuptake inhibition, GABA-A receptor modulation (contributing to anxiolytic effects), and anticonvulsant properties.
Evidence Strength Assessment
The saffron-for-depression literature is unusually strong for a botanical: multiple independent double-blind RCTs with active pharmaceutical comparators, consistent findings across different research groups, and a plausible multi-target mechanism. The main limitations are small sample sizes (most depression trials n = 30–66), predominantly Iranian research groups (raising some generalizability questions), and lack of long-term data beyond 8 weeks. The AMD finding is supported by a methodologically strong crossover design with objective electrophysiological endpoints. Anxiety data is promising but limited to one well-designed RCT. Overall, saffron is among the better-evidenced botanical mood interventions, with an important caveat: it is not a substitute for professional assessment and treatment of clinical depression or anxiety disorders.